Outlook for 2008

Published on 28 October 2008

The outlook estimate has remained the same, with the exception of an updated estimate of annual investment level. Net sales will grow slightly from 2007. Pharmaceutical sales via Orion’s own sales network are expected to continue growing moderately in Finland and to continue showing growth outside Finland. There the growth will nevertheless be slowed down by the expiry at the end of 2007 of the licence agreement for the Calcimagon osteoporosis drug that was marketed in Germany. In-market sales of Parkinson’s drugs will show further growth, but at a slower rate than previously. The deliveries of Parkinson’s drugs to Orion’s marketing partner Novartis are estimated to remain unchanged compared with 2007.

Marketing and research expenditure will increase moderately. Marketing expenses will be rise particularly because of the product launches by Orion’s own units outside Finland. Research expenses will increase mainly due to the clinical studies that were started in the previous year. The on-going patent litigations in the United States will increase administrative expenses in 2008.

Operating profit excluding non-recurring items is estimated to grow slightly from 2007. Such non-recurring items include the one-off compensation of EUR 6 million for the termination of the Calcimagon licence agreement in 2007, and the patent litigation expenses in 2008 that have accounted for EUR 4.4 million in January–September 2008.

R&D expenditure will be slightly over EUR 100 million. Capital expenditure will be about EUR 55 million, not including new substantial product or company acquisitions.

Published on 5 August 2008

Net sales will grow slightly from 2007. Pharmaceutical sales via Orion’s own sales network are expected to continue growing moderately in Finland and to continue showing growth outside Finland, where growth will nevertheless be slowed down by the expiry at the end of 2007 of the licence agreement for the Calcimagon osteoporosis drug that was marketed in Germany. In-market sales of Parkinson’s drugs will show further growth, but at a slower rate than previously. The deliveries of Parkinson’s drugs to Novartis are estimated to remain at the level of 2007.

Marketing and research expenditure will increase moderately. Marketing expenses will be added in particular by the product launches by Orion’s own units outside Finland. Research expenses will grow mainly due to the clinical studies that were started in the previous year. The patent litigations having started in the United States will increase administrative expenses in 2008.

Operating profit excluding non-recurring items is estimated to grow slightly from 2007. Such non-recurring items include the one-off compensation for the termination of the Calcimagon licence agreement in 2007, and the patent litigation expenses in 2008.

R&D expenses will be slightly over EUR 100 million. Capital expenditure will be about EUR 50 million, not including new substantial product or company acquisitions.

Published on 25 April 2008

Net sales will grow slightly from 2007. Pharmaceutical sales via Orion’s own sales network are expected to continue growing moderately in Finland and to continue showing growth outside Finland, where growth will nevertheless be slowed down by the expiry at the end of 2007 of the licence agreement for the osteoporosis drug Calcimagon that was marketed in Germany. In-market sales of Parkinson’s drugs will show further growth, but at a slower rate than previously. The volume of Parkinson’s drugs to be delivered to Novartis is forecast to grow slightly.

Marketing and research expenditure will increase moderately. Marketing expenses will be added in particular by the product launches by Orion’s own units outside Finland. Research expenses will grow mainly due to the clinical studies that were started in the previous year. The patent litigations having started in United States will increase administrative expenses in 2008.

Operating profit excluding non-recurring items is estimated to grow slightly from 2007. Such non-recurring items include the one-off compensation received due to the termination of the Calcimagon licence agreement in 2007, and the patent litigation expenses in 2008.

R&D expenses will be slightly over EUR 100 million. Capital expenditure will be about EUR 40 million, not including substantial product or company acquisitions.

Published on 7 February 2008

Net sales will grow slightly from 2007. Pharmaceutical sales via Orion’s own sales network are expected to continue growing moderately in Finland and to continue showing growth outside Finland, where growth will nevertheless be slowed down by the expiry at the end of 2007 of the licence agreement for the Calcimagon osteoporosis drug that was marketed in Germany. In-market sales of Parkinson’s drugs will show further growth, but at a slower rate than previously. The volume of Parkinson’s drugs to be delivered to Novartis is forecast to grow slightly.

Marketing and research expenditure will increase moderately. Marketing expenses will be added in particular by the product launches by Orion’s own units outside Finland. Research expenses will grow mainly due to the clinical studies that were started in the previous year. The patent litigations having started in United States will increase administrative expenses in 2008.

Operating profit excluding non-recurring items is estimated to grow slightly from 2007. Such non-recurring items include the one-off compensation for the termination of the Calcimagon licence agreement in 2007 and the patent litigation expenses in 2008.

R&D expenses will be slightly over EUR 100 million. Capital expenditure will be about EUR 40 million.